New data on HTI-501 tolerability for cellulite
Halozyme Therapeutics, Inc. has announced interim results from a proof of concept Phase I/II clinical trial evaluating the activity and...
Read MoreJul 3, 2013 | 0 |
Halozyme Therapeutics, Inc. has announced interim results from a proof of concept Phase I/II clinical trial evaluating the activity and...
Read More